Testing a new medication to reduce moderate to severe bowel inflammation

This trial is testing a new medication called Afimkibart to see if it can reduce inflammation and symptoms in people with moderate to severe Crohn's disease. The study will compare people who receive the new medication to people who receive a placebo (a dummy treatment with no active ingredient) to understand how well this treatment works. About 425 people will participate in this double-blind study, meaning neither the participants nor the researchers will know who is getting the real medication.

Many people with Crohn's disease find that standard treatments stop working or don't help them enough. This trial is testing whether this new treatment could offer another option for people whose symptoms remain difficult to control despite using other available medications.